Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a camptothecin analog presented as a sterile powder for intravenous use. It is employed in the treatment of metastatic colorectal cancer and small cell lung cancer in adult patients, and is indicated for those who have progressed after standard therapies.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics where required.

Irinotecan Kabi is a topoisomerase I inhibitor used in oncology for specific solid tumours.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. Small cell lung cancer: used as part of combination chemotherapy for extensive‑stage disease.

Irinotecan Kabi may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Diarrhoea - Neutropenia - Fatigue - Alopecia - Anorexia

Serious or Rare Side Effects: - Febrile neutropenia - Severe diarrhoea or colitis - Hepatic toxicity (elevated transaminases) - Severe allergic reactions (anaphylaxis) - Secondary malignancies - Life‑threatening infections

Before initiating therapy, clinicians should evaluate patient suitability and monitor for toxicity.

Baseline blood counts: assess neutrophil and platelet levels. Liver function: monitor transaminases and bilirubin. Bowel obstruction risk: evaluate for pre‑existing gastrointestinal issues. Dose adjustment: consider hepatic impairment when dosing. Hypersensitivity: avoid in patients with known allergy to irinotecan or formulation components. Store at ambient temperature: keep in original container, protect from moisture and light.

Irinotecan may interact with other medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) - UGT1A1 inhibitors (e.g., atazanavir) - Concurrent myelosuppressive chemotherapy agents - High‑dose radiation therapy to the abdomen

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) - Anticoagulants (may increase bleeding risk) - Diuretics (potential electrolyte disturbances)